- Home
- AR vs EXAS Comparison
AR vs EXAS Comparison
Compare AR & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AR
- EXAS
- Stock Information
- Founded
- AR 2002
- EXAS 1995
- Country
- AR United States
- EXAS United States
- Employees
- AR N/A
- EXAS N/A
- Industry
- AR Oil & Gas Production
- EXAS Medical Specialities
- Sector
- AR Energy
- EXAS Health Care
- Exchange
- AR Nasdaq
- EXAS Nasdaq
- Market Cap
- AR 9.9B
- EXAS 11.0B
- IPO Year
- AR 2013
- EXAS N/A
- Fundamental
- Price
- AR $31.88
- EXAS $63.30
- Analyst Decision
- AR Buy
- EXAS Strong Buy
- Analyst Count
- AR 16
- EXAS 21
- Target Price
- AR $43.87
- EXAS $69.24
- AVG Volume (30 Days)
- AR 4.0M
- EXAS 2.1M
- Earning Date
- AR 10-29-2025
- EXAS 11-03-2025
- Dividend Yield
- AR N/A
- EXAS N/A
- EPS Growth
- AR 4491.03
- EXAS N/A
- EPS
- AR 1.52
- EXAS N/A
- Revenue
- AR $4,870,111,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- AR $24.16
- EXAS $16.68
- Revenue Next Year
- AR $6.58
- EXAS $12.12
- P/E Ratio
- AR $21.01
- EXAS N/A
- Revenue Growth
- AR 11.79
- EXAS 12.55
- 52 Week Low
- AR $25.36
- EXAS $38.81
- 52 Week High
- AR $44.02
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- AR 45.31
- EXAS 70.33
- Support Level
- AR $31.66
- EXAS $63.05
- Resistance Level
- AR $33.06
- EXAS $65.44
- Average True Range (ATR)
- AR 1.13
- EXAS 1.56
- MACD
- AR -0.00
- EXAS 0.02
- Stochastic Oscillator
- AR 36.89
- EXAS 72.22
About AR Antero Resources Corporation
Antero Resources, based in Denver, explores for and produces natural gas and natural gas liquids in the United States and Canada. At the end of 2024, the company reported proven reserves of 17.9 trillion cubic feet of natural gas equivalent. Production averaged approximately 3,424 million cubic feet of equivalent a day in 2024 at a ratio of 35% liquids and 65% natural gas.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.